Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has successfully included several of its products in the National Medical Insurance Directory, which is expected to enhance the accessibility of its medications and potentially increase sales revenue [1] Group 1: Inclusion of Products - The following products have been newly included in the National Medical Insurance Directory: injection of Rukang Qutuzumab, Apixaban Famitinib Capsules, injection of Funaqi Zhumab, Sulfate Amasitinib Tablets, injection of Phosphorola Pitant Palonosetron, injection of Ruikasi Dantab, Acetate Abiraterone Tablets (II), Liposomal Irinotecan Injection (II), and Regaglitin Metformin Tablets (I)/(II), as well as Perfluorohexyl Octane Eye Drops [1] - New indications for the following products have also been successfully added: injection of Karilizumab, Fluorouracil Capsules, and injection of Fumaric Acid Tegafur [1] - The following products have successfully renewed their contracts to remain in the National Medical Insurance Directory: Maleate Pyrotinib Tablets, Hecorapam Ethanolamine Tablets, Phosphate Regaglitin Tablets, injection of Tanshinone IIA, and Sulfate Pevonedistat Injection [1] Group 2: Adjustments and Management - The indications for Methoxamine Apatinib Tablets and Bupivacaine Liposome Injection have been newly added and adjusted to regular directory management [1]

Core Viewpoint - Heng Rui Medicine announced the inclusion of several drugs in the national medical insurance directory, which is expected to positively impact sales, although the exact effect on the company's performance is currently indeterminate [1] Group 1: Drug Inclusion in National Medical Insurance - The following drugs have been newly included in the national medical insurance directory: injection of Rukang Qumatuozhuzhantang, Appleseed Famitinib capsules, injection of Funachizhu single antibody, and several others [1] - New indications for injection of Karilizhu single antibody, Fluorozolpali capsules, and Fumaric acid Tejilidin injection have also been successfully added to the national medical insurance directory [1] - The renewal of the following drugs has been successful, allowing them to remain in the national medical insurance directory: Malate Pyrotinib tablets, Hecoropag Ethanolamine tablets, and several others [1] Group 2: Financial Impact - The total sales revenue for the aforementioned drugs is estimated to be approximately 8.66 billion yuan for the year 2024 [1] - For the first three quarters of 2025, the estimated sales revenue for these drugs is around 7.55 billion yuan [1] - The inclusion of these drugs in the national medical insurance directory is expected to facilitate sales, although the specific impact on the company's operational performance remains uncertain [1]

Core Viewpoint - Heng Rui Medicine (600276) announced on December 7 that several of its products have been included in the National Medical Insurance Directory as per the notice from the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] Group 1: Inclusion in National Medical Insurance Directory - The following products have been newly included in the National Medical Insurance Directory: Injection of Rukang Qutuzumab, Apixaban Famitinib Capsules, Injection of Funaqi Qutuzumab, Sulfate of Amagatinib Tablets, Injection of Phosphororapitant Palonosetron, Injection of Ruikaxizumab, Acetate of Abiraterone Tablets (II), Lipid Injection of Irinotecan Hydrochloride (II), and Regaglitin Metformin Tablets (I)/(II), as well as Perfluorohexyl Octanoate Eye Drops [1] - The following products have successfully added new indications to the National Medical Insurance Directory: Injection of Karilizumab, Fluorazepam Capsules, and Injection of Fumaric Acid Tegafur [1] - The following products have successfully renewed their contracts to remain in the National Medical Insurance Directory: Maleate of Pyrotinib Tablets, Hecorapam Ethanolamine Tablets, Phosphate of Regaglitin Tablets, Injection of Tansuzumab, and Sulfate of Pevotizumab Injection [1] Group 2: Adjustments and Management - The indications for Methoxysulfonamide Apatinib Tablets and Lipid Injection of Bupivacaine have been newly added and adjusted to regular directory management [1]